1 |
吴彩娟,余玉香,罗健, 等. 宫颈疾病与生殖道高危型人乳头状瘤病毒感染的相关性分析[J]. 中华医院感染学杂志,2013,23(8):1843-1845.
|
2 |
赵莲莲. 人乳头瘤病毒疫苗在宫颈癌前病变,宫颈癌预防中的研究进展[J]. 中华灾害救援医学,2015,3(4):227-230.
|
3 |
Vijayaraghavan A, Efrusy MB, Mayrand MH, et al. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada[J]. Can J Public Health,2010,101(3):220-225.
|
4 |
王永春. 高危型人乳头瘤病毒感染与宫颈病变关系的研究[J]. 临床合理用药杂志,2012,5(33):9-10.
|
5 |
段仙芝,宋艳波,王少明, 等. 宫颈液基细胞学结果与高危型人乳头瘤病毒的相关性[J]. 中国肿瘤,2015,24(1):76-78.
|
6 |
LD Ríoospina, SD León, M Camargo, et al. The DNA load of six high-risk human papillomavirus types and its association with cervical lesions[J]. BMC cancer,2015,15(1):1126-1127.
|
7 |
Chagas BS, Comar M, Gurgel AP, et al. Association study between cervical lesions and single or multiple vaccine-target and non-vaccine target human papilloma virus (HPV) types in women from Northeastern Brazil[J]. PLoS One,2015,10(7):e0132570.
|
8 |
叶英. 慢性宫颈炎合并人乳头瘤病毒感染的临床研究[J/CD]. 中华实验和临床感染病杂志(电子版),2013,7(3):115-117.
|
9 |
Daponte A, Pournaras S, Tsakris A, et al. Self-sampling for high-risk human papillomavirus detection: future cervical cancer screening[J]. Women S Health,2014,10(2):115-118.
|
10 |
李莉. 120例高危型人乳头瘤病毒感染检测及宫颈病变影响因素的探讨[J]. 中国医药导报,2015,1(14):49-50.
|
11 |
康乐妮,赵方辉,陈凤, 等. 高危型人乳头瘤病毒载量预测宫颈病变和分流人乳头瘤病毒阳性人群的价值[J]. 中华肿瘤杂志,2014,36(4):316-320.
|
12 |
司炎辉,刘保池,黄朝刚. 人类免疫缺陷病毒与人乳头瘤病毒共感染的临床特征分析[J/CD]. 中华实验和临床感染病杂志(电子版),2015,9(5):54-57.
|
13 |
Tjalma WA, Trinh XB, Rosenlund M, et al. A cross-sectional, multicentre, epidemiological study on human papillomavirus (HPV) type distribution in adult women diagnosed with invasive cervical cancer in Belgium[J]. Facts Views Vis Obgyn,2015,7(2):101-108.
|
14 |
Kumar S, Jena L, Sahoo M, et al. In silico docking to explicate interface between plant-originated inhibitors and E6 oncogenic protein of highly threatening human papilloma virus 18[J]. Genomics Inform,2015,13(2):60-67.
|
15 |
赵旭晔,崔勇,姜淑芳, 等. 高危型人乳头瘤病毒E6/E7 mRNA检测在宫颈癌筛查中的意义[J]. 中华医学杂志,2014,94(43):3432-3435.
|
16 |
Cistjakovs M, Sultanova A, Jermakova O, et al. Human papillomavirus type 18 infection in a female renal allograft recipient: a case report[J]. J Med Case Rep,2016,10(1):318.
|
17 |
Gage JC, Hunt WC, Schiffman M, et al. Similar risk patterns after cervical screening in two large U.S. populations: implications for clinical guidelines[J]. Obstet Gynecol,2016,128(6):1248-1257.
|
18 |
Virtanen E, Pietilä T, Nieminen P, et al. Low expression levels of putative HPV encoded microRNAs in cervical samples[J]. Springerplus,2016,5(1):1856.
|
19 |
Zhang Q, Liu YJ, Hu SY, et al. Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China[J]. BMC Cancer,2016,16(1):848.
|
20 |
Stuqui B, Conceição AL, Termini L, et al. The differential role of HTRA1 in HPV-positive and HPV-negative cervical cell line proliferation[J]. BMC Cancer,2016,16(1):840.
|